Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) CEO Sells 5,147 Shares of Stock

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Get Free Report) CEO Richard E. Lowenthal sold 5,147 shares of the company's stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $9.05, for a total transaction of $46,580.35. Following the completion of the sale, the chief executive officer now directly owns 1,642,193 shares in the company, valued at $14,861,846.65. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

ARS Pharmaceuticals Price Performance

Shares of ARS Pharmaceuticals stock traded up $0.22 during trading on Thursday, reaching $9.10. 404,491 shares of the company traded hands, compared to its average volume of 583,246. ARS Pharmaceuticals, Inc. has a 1-year low of $2.55 and a 1-year high of $11.27. The company has a 50 day moving average price of $9.07 and a 200-day moving average price of $6.96. The firm has a market capitalization of $881.70 million, a PE ratio of -17.50 and a beta of 0.88.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.11). Equities research analysts expect that ARS Pharmaceuticals, Inc. will post -0.68 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its holdings in ARS Pharmaceuticals by 22,300.0% during the fourth quarter. Nisa Investment Advisors LLC now owns 5,600 shares of the company's stock worth $31,000 after buying an additional 5,575 shares during the last quarter. AJOVista LLC acquired a new position in ARS Pharmaceuticals during the fourth quarter worth $43,000. Russell Investments Group Ltd. acquired a new position in ARS Pharmaceuticals during the first quarter worth $60,000. China Universal Asset Management Co. Ltd. raised its holdings in ARS Pharmaceuticals by 352.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 11,105 shares of the company's stock worth $61,000 after buying an additional 8,652 shares during the last quarter. Finally, Paloma Partners Management Co acquired a new position in ARS Pharmaceuticals during the first quarter worth $103,000. Institutional investors and hedge funds own 68.16% of the company's stock.

Analyst Upgrades and Downgrades

SPRY has been the topic of a number of analyst reports. William Blair raised shares of ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a research note on Tuesday, February 20th. Leerink Partnrs raised shares of ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 5th. SVB Leerink raised shares of ARS Pharmaceuticals from a "market perform" rating to an "outperform" rating and upped their price objective for the company from $6.00 to $18.00 in a research note on Tuesday, March 5th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $19.00 price objective on shares of ARS Pharmaceuticals in a research note on Monday, March 11th.

ARS Pharmaceuticals Company Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.